Global Cardiovascular Biomaterial Market
市场规模（十亿美元）
CAGR :
% 
 Forecast Period |
2024 –2031 |
 Market Size (Base Year) |
USD 13.58 Billion |
 Market Size (Forecast Year) |
USD 22.86 Billion |
 CAGR |
% |
| Major Markets Players |
全球心血管生物材料市场细分，按类型（天然、陶瓷、金属和聚合物）、产品（导管、支架、植入式心脏除颤器、起搏器、传感器、心脏瓣膜、血管移植物、导丝和心室辅助装置）– 行业趋势和预测至 2031 年
心血管生物材料市场分析
由于心血管疾病发病率不断上升以及医疗器械和植入物中使用的生物材料的进步，心血管生物材料市场正在经历显著增长。这些材料包括金属、聚合物、陶瓷和复合材料，在支架、心脏瓣膜、起搏器和血管移植物等设备的开发中发挥着关键作用。市场受到微创手术需求不断增长、材料性能改善以及心血管医疗保健对定制治疗日益增长的需求的驱动。最近的发展包括生物可吸收聚合物和心脏瓣膜置换术的创新，旨在改善患者预后同时减少并发症。老龄化人口的不断增长以及先进生物材料技术的日益普及进一步推动了市场增长。此外，医疗器械制造商和生物材料供应商之间的合作正在加强该领域的研究和产品开发，为心血管生物材料市场提供了有希望的增长机会。
心血管生物材料市场规模
2023 年全球心血管生物材料市场规模价值 135.8 亿美元，预计到 2031 年将达到 228.6 亿美元，2024 年至 2031 年预测期内的复合年增长率为 6.72%。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的见解外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、管道分析、定价分析和监管框架。
心血管生物材料市场趋势
《心血管疾病的先进治疗》
The cardiovascular biomaterials market is witnessing significant growth, driven by the increasing demand for advanced materials in the treatment of cardiovascular diseases. Innovations in biomaterials, such as bioresorbable stents, and the development of self-healing materials are transforming treatment options. One notable trend is the shift toward minimally invasive procedures, facilitated by the use of advanced biomaterials such as polymers and composites. These materials offer enhanced biocompatibility, reduced risk of rejection, and improved performance. The growing focus on personalized medicine and tailored cardiovascular solutions is further pushing innovation in this market. As a result, cardiovascular biomaterials are becoming essential for developing next-generation medical devices, contributing to better patient outcomes and fueling market growth.
Report Scope and Cardiovascular Biomaterial Market Segmentation
|
Attributes |
Cardiovascular Biomaterial Key Market Insights |
|
Segments Covered |
|
|
Countries Covered |
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America. |
|
Key Market Players |
DSM-Firmenich (Netherlands), Wright Medical Group N.V. (U.S.), Zimmer Biomet (U.S.), Bayer AG (Germany), BASF (Germany), CRS Holdings LLC. (U.S.), Invibio Ltd. (U.K.), Foster Corporation (U.S.), CVD Equipment Corporation (U.S.), Abbott (U.S.), Baxter (U.S.), Medtronic (Ireland), Johnson & Johnson Private Limited (U.S.), Boston Scientific Corporation (U.S.), Edwards Lifesciences Corporation (U.S.), BD (U.S.), Molnlycke Health Care AB (Sweden), Smith+Nephew (U.K.), Integra LifeSciences Corporation (U.S.), Messe-Düsseldorf GmbH (Germany), AnteoTech (Australia), and ANYGEN (South Korea) |
|
Market Opportunities |
|
|
Value Added Data Infosets |
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework. |
Cardiovascular Biomaterial Market Definition
Cardiovascular biomaterials are specialized materials used in the development of medical devices and implants designed for the treatment of cardiovascular diseases. These materials, which can be natural or synthetic, include metals, polymers, ceramics, and composites. They are used in products such as stents, heart valves, pacemakers, vascular grafts, and other cardiovascular devices. The primary goal of cardiovascular biomaterials is to ensure compatibility with the human body, promote tissue healing, reduce the risk of complications, and improve the performance and longevity of the implanted devices.
Cardiovascular Biomaterial Market Dynamics
Drivers
- Rising Prevalence of Cardiovascular Diseases
The increasing prevalence of heart conditions, such as coronary artery diseases, heart failure, and arrhythmias, is a significant driver of the cardiovascular biomaterials market. As these conditions become more common due to factors such as aging populations, sedentary lifestyles, and unhealthy diets, there is a rising demand for effective treatments, including biomaterial-based implants. These implants, such as stents, heart valves, and pacemakers, help address cardiovascular issues by improving blood flow, stabilizing heart rhythms, and replacing damaged heart valves. The need for these solutions contributes to the growing adoption of advanced biomaterials, accelerating the market's expansion.
- Minimally Invasive Procedures
The growing preference for minimally invasive cardiovascular procedures is a key driver of the cardiovascular biomaterials market. These procedures, which utilize advanced biomaterials such as bioresorbable stents, vascular grafts, and heart valves, offer several benefits over traditional open-heart surgeries, including smaller incisions, reduced risk of infection, and quicker recovery times. Patients experience less trauma, shorter hospital stays, and a faster return to normal activities, contributing to improved overall outcomes. The increasing shift toward these procedures, supported by continuous advancements in biomaterial technology, is driving the demand for innovative solutions, thus fostering market growth.
Opportunities
- Development of Bioresorbable Materials
The rise of bioresorbable stents and scaffolds is a major opportunity in the cardiovascular biomaterials market. These devices offer the advantage of gradually dissolving within the body after serving their purpose, eliminating the need for permanent implants. This reduces the risk of long-term complications such as inflammation, thrombosis, or restenosis that can occur with traditional metallic stents. As the demand for more advanced and patient-friendly solutions increases, bioresorbable biomaterials are gaining traction. Their potential to improve patient outcomes by minimizing the need for further surgeries and reducing healthcare costs drives the demand for these innovative biomaterials, creating significant market growth opportunities.
- Advancements in 3D Printing
The integration of 3D printing technology in creating customized cardiovascular devices presents a significant opportunity for innovation in the biomaterials market. By using 3D printing, manufacturers can design and produce devices that are precisely tailored to a patient's unique anatomy and medical needs. This can lead to improved outcomes, as the devices can be optimized for better fit and function, particularly for complex cases. Customization through 3D printing allows for more personalized treatment, enhancing the patient experience and reducing the likelihood of complications. As the technology advances, it is expected to drive the growth of cardiovascular biomaterials, offering unique, patient-specific solutions.
Restraints/Challenges
- Competition and Market Fragmentation
The cardiovascular biomaterials market is highly competitive, with numerous companies offering similar products such as stents, heart valves, and grafts. This intense competition can lead to price wars, where manufacturers lower their prices to attract customers, ultimately reducing profit margins. Additionally, the presence of multiple players offering comparable solutions makes it challenging to differentiate new technologies. Innovations in materials or design may not always stand out in a crowded marketplace, slowing adoption and hindering companies from gaining a competitive edge. As a result, firms must invest in unique value propositions and effective marketing strategies to overcome these challenges and stand out.
- High Costs of Advanced Materials
The production of advanced cardiovascular biomaterials, including bioresorbable stents and customized 3D-printed devices, involves high manufacturing costs due to the complexity of the materials and technologies required. These elevated costs can limit accessibility, particularly in developing regions with less advanced healthcare infrastructure. Patients without adequate insurance coverage may also face financial barriers, restricting their ability to afford these cutting-edge treatments. This price disparity between high-cost innovations and more affordable traditional options can slow the widespread adoption of advanced cardiovascular biomaterials, posing a significant restraint to market growth and limiting access to life-saving therapies for many.
This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Cardiovascular Biomaterial Market Scope
The market is segmented on the basis of type and product. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Natural
- Ceramic
- Metallic
- Polymer
Product
- Catheters
- Stents
- Implantable Cardiac Defibrillators
- Pacemakers
- Sensors
- Heart Valves
- Vascular Grafts
- Guidewires
- Ventricular Assist Devices
Cardiovascular Biomaterial Market Regional Analysis
The market is analysed and market size insights and trends are provided by country, type, and product as referenced above.
The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
受医疗技术进步和心血管疾病高发性的推动，北美有望成为心血管生物材料市场的领导者。这些疾病通常会导致严重的、不可逆的器官损伤，对有效的生物材料治疗产生强烈需求。因此，该地区越来越多地采用心血管生物材料来应对这些医疗保健挑战。
预计从 2024 年到 2031 年，亚太地区的心血管生物材料市场将出现最快的增长。这一增长是由该地区心血管疾病和心脏相关疾病的患病率不断上升所推动的。对解决这些健康挑战的先进治疗方案的需求不断增加，推动了市场的扩张。
报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的大量或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。
心血管生物材料市场份额
市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对市场的关注有关。
在市场上运营的心血管生物材料市场领导者是：
- dsm-firmenich (荷兰)
- Wright Medical Group NV（美国）
- Zimmer Biomet（美国）
- 拜耳公司（德国）
- 巴斯夫（德国）
- CRS Holdings LLC.（美国）
- Invibio Ltd.（英国）
- 福斯特公司（美国）
- CVD 设备公司（美国）
- 雅培（美国）
- 百特（美国）
- 美敦力（爱尔兰）
- 强生私人有限公司（美国）
- 波士顿科学公司 (美国)
- 爱德华生命科学公司（美国）
- BD（美国）
- Molnlycke Health Care AB（瑞典）
- Smith+Nephew（英国）
- Integra LifeSciences Corporation（美国）
- 杜塞尔多夫展览有限公司 (德国)
- AnteoTech（澳大利亚）
- ANYGEN (韩国)
心血管生物材料市场最新发展
- 2023 年 10 月，医疗技术领导者雅培宣布收购 Tendyne Holding, Inc. 此次战略收购通过整合经导管二尖瓣置换 (TMVR) 疗法增强了雅培的结构性心脏产品组合。此举增强了雅培提供先进心脏瓣膜解决方案的能力，并扩大了其在结构性心脏市场的影响力
- 2023 年 8 月，Zimmer Biomet 推出了 Persona Q-Fix 股骨系统，这是微创全髋关节置换术 (THA) 的重大进步。该创新系统旨在提高手术效率，并通过更简化的方法为外科医生提供更好的控制。此次发布标志着改善患者治疗效果和简化 THA 程序的一项关键进展
- 2023 年 5 月，强生公司的医疗器械部门宣布与心血管成像解决方案 (CIS) 合作，开发和商业化用于外周血管介入的下一代血管内成像系统。此次合作利用了 CIS 在光学相干断层扫描 (OCT) 技术方面的专业知识以及强生在医疗器械开发和商业化方面的优势。该联盟旨在提高成像能力并改善外周血管手术的患者预后
- 2023 年 4 月，CRS Holdings Inc. 和 Bioventus LLC 合并，成立 Bioventus 旗下的单一实体，标志着生物材料市场的一个重要里程碑。此次合并旨在打造骨科生物和软组织解决方案领域的全球领导者，利用研发、制造和分销方面的协同效应。合并后的公司旨在推动创新，特别是在心血管生物材料领域
- 2023 年 2 月，科思创推出了专为医疗保健和生命科学应用而设计的 Makrolon 3638 聚碳酸酯。这种耐用的聚碳酸酯等级经过精心设计，可承受日常使用，同时保持其结构完整性。此次发布彰显了科思创致力于为关键医疗和科学用途提供高性能材料的承诺
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
